|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | |||||||||
  British Journal of DermatologyVolume 118 Issue 5, Pages 687 - 691 Published Online: 29 Jul 2006 Journal compilation © 2010 British Association of Dermatologists An Official Journal of the British Association of Dermatologists
Abstract | References | Full Text: PDF (Size: 1434K) | Related Articles | Citation Tracking  Tolerance of spironolactone Copyright 1988 British Association of Dermatologists ABSTRACT
A survey of 54 patients taking spironolactone for hirsutes or acne showed that side-effects occurred in 91%; in 80% of patients, these were related to the anti-androgenic mechanism of the drug (menstrual disturbances, and breast enlargement and tenderness). The concomitant use of a contraceptive pill gave a lower incidence of menstrual abnormalities. Only seven patients (13%) had to stop the drug. In a further eight patients, a reduction in dose to between 125 and 175 mg daily achieved a compromise of controlling the disease and the side-effects. Side-effects tended to occur early and so regular review during the initial 3 months of treatment is advised. Two patients in our study developed 'chloasma'—a previously unreported complication of spironolactone. This was the only side-effect which occurred late in treatment. Accepted for publication 19 November 1987 | 
|
